 |
366 Diseases |  |
40 Trials |
|
40 Trials |  |
1661 News |  |
| «12...11121314151617181920212223» |
- Enrollment open, Metastases: MetAction: N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (clinicaltrials.gov) - May 20, 2014
P2, N=50, Recruiting, Sponsor: Oslo University Hospital
Not yet recruiting --> Recruiting
- Torisel (temsirolimus) / Pfizer
Biomarker, Trial primary completion date: FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib (clinicaltrials.gov) - May 20, 2014
P1, N=5, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Jun 2015
- Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - May 20, 2014
P1/2, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Jun 2015 Active, not recruiting --> Completed
- Zarnestra (tipifarnib) / Kura Oncology, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (clinicaltrials.gov) - May 20, 2014
P1/2, N=183, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=90 --> 183
- perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Trial primary completion date: Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma (clinicaltrials.gov) - May 19, 2014
P1/2, N=92, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=90 --> 183 Trial primary completion date: Jun 2014 --> Jun 2015
- Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Surgery, Metastases: Selumetinib With or Without Temsirolimus in Treating Patients With Metastatic, Recurrent, or Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed By Surgery (clinicaltrials.gov) - May 18, 2014
P2, N=70, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2014 --> Jun 2015 Trial primary completion date: Jun 2014 --> Jun 2015
- New P2 trial, Metastases: MetAction: N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (clinicaltrials.gov) - May 18, 2014
P2, N=50, Not yet recruiting, Sponsor: Oslo University Hospital
- Torisel (temsirolimus) / Pfizer
Trial completion date: Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 11, 2014
P1/2, N=12, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jun 2014 --> Jun 2015 Trial completion date: Mar 2014 --> May 2015
- Torisel (temsirolimus) / Pfizer
Metastases: FLT-PET in Predicting Response to Chemotherapy in Patients With Advanced Malignancies (clinicaltrials.gov) - May 11, 2014
P=N/A, N=16, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial completion date: Mar 2014 --> May 2015 Trial primary completion date: Apr 2015 --> Apr 2016
- RG4733 / Roche, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Combination therapy, Metastases: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2014
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Apr 2015 --> Apr 2016 Trial primary completion date: May 2013 --> Jul 2013
- || Nerlynx (neratinib) / Puma
Trial primary completion date, Metastases: Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=65, Recruiting, Sponsor: Puma Biotechnology, Inc.
Trial primary completion date: May 2013 --> Jul 2013 Trial primary completion date: Mar 2014 --> Dec 2015
- || Nerlynx (neratinib) / Puma
Trial completion date, Metastases: Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer (clinicaltrials.gov) - May 6, 2014
P1/2, N=65, Recruiting, Sponsor: Puma Biotechnology, Inc.
Trial primary completion date: Mar 2014 --> Dec 2015 Trial completion date: Mar 2014 --> Dec 2015
- RG4733 / Roche, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy, Metastases: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2014
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
Trial completion date: Mar 2014 --> Dec 2015 N=30 --> 18
- RG4733 / Roche, Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy, Metastases: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 6, 2014
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
N=30 --> 18 Active, not recruiting --> Completed
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Trial primary completion date, Metastases: Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (clinicaltrials.gov) - May 5, 2014
P2, N=172, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Apr 2014 --> Jul 2014
- ||||| Fotivda (tivozanib) / Kyowa Kirin, AVEO, Jazz
Trial initiation date: A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols (clinicaltrials.gov) - May 1, 2014
P2/3, N=230, Ongoing, Sponsor: AVEO Pharmaceuticals, Inc.`AVEO PHARMACEUTICALS, INC.
Trial primary completion date: Apr 2014 --> Jul 2014 Initiation date: Jun 2010 --> Oct 2010
- Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV (clinicaltrials.gov) - Apr 28, 2014
P2, N=35, Terminated, Sponsor: National Cancer Institute (NCI)
Initiation date: Jun 2010 --> Oct 2010 N=15 --> 35
- Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy, Metastases: Temsirolimus in Combination With Metformin in Patients With Advanced Cancers (clinicaltrials.gov) - Apr 23, 2014
P1, N=104, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=15 --> 35 N=64 --> 104
- Votrient (pazopanib) / Novartis, BeiGene
New P2 trial, Metastases: Second Line Sorafenib After Pazopanib in Patients With RCC (clinicaltrials.gov) - Apr 22, 2014
P2, N=44, Not yet recruiting, Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer (clinicaltrials.gov) - Apr 17, 2014
P2, N=67, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=64 --> 104 N=84 --> 67
- | Torisel (temsirolimus) / Pfizer
Trial completion: CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Apr 14, 2014
P2, N=27, Completed, Sponsor: National Cancer Institute (NCI)
N=84 --> 67 Active, not recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy: Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Apr 8, 2014
P1, N=72, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed N=106 --> 72
- Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy: Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors (clinicaltrials.gov) - Apr 8, 2014
P1, N=72, Completed, Sponsor: National Cancer Institute (NCI)
N=106 --> 72 Active, not recruiting --> Completed
- || Koselugo (selumetinib) / Merck (MSD), AstraZeneca
Enrollment change, Combination therapy, Metastases: A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) (clinicaltrials.gov) - Apr 6, 2014
P1, N=211, Active, not recruiting, Sponsor: AstraZeneca
Active, not recruiting --> Completed N=80 --> 211
- Avastin (bevacizumab) / Roche, Torisel (temsirolimus) / Pfizer
Enrollment open, Metastases: Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer (clinicaltrials.gov) - Apr 3, 2014
P2, N=299, Recruiting, Sponsor: National Cancer Institute (NCI)
N=80 --> 211 Suspended --> Recruiting
- Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Trial suspension: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Mar 31, 2014
P2, N=74, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- trebananib (AMG 386) / Amgen, Torisel (temsirolimus) / Pfizer
Enrollment closed, Surgery, Metastases: Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (clinicaltrials.gov) - Mar 31, 2014
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
New P2a trial, P2 data, P2a data: POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus (clinicaltrials.gov) - Mar 19, 2014
P2a, N=10, Completed, Sponsor: Medica Scientia Innovation Research
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment change, Combination therapy, Metastases: Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Mar 19, 2014
P1/2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=68 --> 48
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy, Metastases: Cixutumumab and Temsirolimus in Treating Patients With Locally Recurrent or Metastatic Breast Cancer (clinicaltrials.gov) - Mar 19, 2014
P1/2, N=48, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=68 --> 48 Suspended --> Active, not recruiting
- ||||| Torisel (temsirolimus) / Pfizer
Enrollment closed: RAY : Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy (clinicaltrials.gov) - Mar 9, 2014
P3, N=280, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Suspended --> Active, not recruiting Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Enrollment closed, Metastases: Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma (clinicaltrials.gov) - Mar 3, 2014
P2, N=86, Active, not recruiting, Sponsor: AGO Study Group
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Torisel (temsirolimus) / Pfizer
Trial termination, Metastases: Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis (clinicaltrials.gov) - Mar 2, 2014
P2, N=6, Terminated, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Active, not recruiting Recruiting --> Terminated; The study treminated early according to DSMB recommendantions
- Torisel (temsirolimus) / Pfizer
Enrollment change, Metastases: Temsirolimus in Treating Patients With Advanced Liver Cancer and Cirrhosis (clinicaltrials.gov) - Mar 2, 2014
P2, N=6, Terminated, Sponsor: Federation Francophone de Cancerologie Digestive
Recruiting --> Terminated; The study treminated early according to DSMB recommendantions N=50 --> 6
- | Torisel (temsirolimus) / Pfizer
Trial completion: Single Agent Temsirolimus (Torisel (clinicaltrials.gov) - Feb 27, 2014
P2, N=21, Completed, Sponsor: Oncology Specialists, S.C.
N=50 --> 6 Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion, Stroma: CCI-779 in Treating Patients With Soft Tissue Sarcoma or Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Feb 22, 2014
P2, N=55, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion, Combination therapy, Metastases: CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=42, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion: CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase (clinicaltrials.gov) - Feb 22, 2014
P2, N=74, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion: Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Feb 22, 2014
P2, N=25, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=50, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- ||||||| Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma (clinicaltrials.gov) - Feb 22, 2014
P3, N=626, Completed, Sponsor: Pfizer
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion: CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov) - Feb 22, 2014
P2, N=80, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion: CCI-779 in Treating Patients With Malignant Glioma (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: North American Brain Tumor Consortium
Active, not recruiting --> Completed No longer recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion: CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme (clinicaltrials.gov) - Feb 19, 2014
P2, N=33, Completed, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Torisel (temsirolimus) / Pfizer
Trial completion, Metastases: A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer (clinicaltrials.gov) - Feb 11, 2014
P1, N=47, Completed, Sponsor: Georgetown University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- rhIL-15 / National Cancer Institute
Trial completion, Metastases: A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer (clinicaltrials.gov) - Feb 4, 2014
P1, N=18, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Completed
- Torisel (temsirolimus) / Pfizer
Trial completion, Surgery, Metastases: Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery (clinicaltrials.gov) - Jan 26, 2014
P2, N=32, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- Zolinza (vorinostat) / Merck (MSD), Torisel (temsirolimus) / Pfizer
Enrollment change, Epigenetic controller, Metastases: Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer (clinicaltrials.gov) - Jan 8, 2014
P1, N=219, Recruiting, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=107 --> 219
- cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
Enrollment closed, Combination therapy: Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (clinicaltrials.gov) - Jan 5, 2014
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=107 --> 219 Suspended --> Active, not recruiting